GE HealthCare Technologies Inc. (GEHC) 2024 10-K Earnings Analysis
GE HealthCare Technologies Inc.2024 Earnings Analysis
75/100
GE HealthCare Technologies Inc.'s FY2024 numbers are straightforward on the surface but more interesting underneath: $19.7B of revenue, $1.99B of net income, 41.7% gross margin, and negative free cash flow of $401M. January 2023 GE Spin-Off, Hospital CapEx Cycle, and Siemens / Philips Competition remain the clearest way to understand where the economics come from and why margin durability looks different here than it would at a generic peer. January 2023 GE Spin-Off helped keep gross margin at 41.7% and operating margin at 13.3%, so the economics still look earned. What matters next is whether Hospital CapEx Cycle and Siemens / Philips Competition stay contained at the same time.
Filing analysis
GE HealthCare Technologies Inc. 2024 10-K Analysis
This page reads GE HealthCare Technologies Inc.'s 2024 10-K annual report through the EarningsMoat framework: earnings quality, economic moat strength, capital allocation, and key risks. The current overall score is 75/100, or grade C.
GEHC Earnings Quality
The earnings-quality module scores 75/100, with Gross Margin: 41.7%, Operating Margin: 13.3%. The core question is whether reported profit is backed by operating cash flow and recurring business economics. See the earnings quality analysis guide.
GEHC Economic Moat Analysis
The moat-strength module scores 80/100, with Imaging Platform Lead: MR/CT/Ultrasound, Service Network: Installed-base monetization. The test is whether the advantage can protect returns after competitors react. Read the economic moat analysis guide.
GEHC Free Cash Flow vs Net Income
Free cash flow versus net income is the fastest read on whether accounting earnings turn into cash. The capital-allocation module scores 73/100. For the diagnostic, start with cash flow vs net income.
GEHC Key Risks from the Annual Report
The risk module scores 70/100, with Hospital CapEx Cycle: Capital-equipment cycle, China Hospital Spending: VBP/policy headwinds. The goal is to separate ordinary disclosure from risks that can change margins, cash flow, leverage, or the moat itself.
Is GEHC a High Quality Earnings Stock?
Based on this 2024 filing, GEHC needs a closer read before it qualifies as a high-quality earnings candidate: the overall grade is C, and the earnings-quality score is 75/100. This is a research screen, not investment advice.
Read the report first
Understand GE HealthCare Technologies Inc. first, then decide if it belongs on your watchlist
The GEHC score, explanation, management facts, and filing sources are all here. When you want to follow more companies, review new-filing changes, or keep notes for the next review, keep more names in your watchlist.
Read the report first
Understand the company first. Keep up with every filing as your list grows.
A single report helps you judge one company. As your watchlist grows, review score, cash flow, moat, and risk changes together instead of repeating the same work.
Keep more names together
When your list grows, keep GEHC with the rest of your names and review score, grade, and risk changes over time.
See how to track more namesAsk follow-up questions
Dig into cash conversion, moat evidence, capital allocation, and risk changes without rereading the full 10-K.
Ask a questionExport and revisit records
Save the GEHC report as research notes you can revisit before the next filing.
Save research notesCore Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Overall Score Trend
Earnings Quality
A better way to read gross margin is to notice that a better way to read gross margin is to notice that gross margin of 41.7% reflects the disclosed medical imaging and diagnostics product-mix economics.
Operating Margin is not just a statistic here; it shows that operating Margin is not just a statistic here; it shows that the 13.3% operating margin reflects the disclosed Imaging and PCS and PDx and AVS multi segment mix economics — post spin off operating-discipline trajectory per the disclosed strategic-priority communications.
The significance of roe in FY2024 is that the significance of roe in FY2024 is that ROE of 23.6% reflects medical equipment and imaging asset returns per the segment-disclosure communications.
There is enough internal consistency in FY2024 to trust the numbers: $1.99B of net income, negative free cash flow of $401M, and 41.7% gross margin all fit together. January 2023 GE Spin-Off sits close enough to the core workflow that it supports both margin retention and cash conversion, and Hospital CapEx Cycle reinforces that pattern. That left the company with 13.3% operating margin before capital allocation choices came into view. The weak point in the file is cash conversion around January 2023 GE Spin-Off, not the top-line revenue figure.
Moat Strength
Imaging Platform Lead helps explain why imaging Platform Lead helps explain why and ultrasound per public industry rankings — alongside Siemens Healthineers and Philips per the disclosed competitive landscape.
Read service network as evidence that read service network as evidence that GEHC's service and recurring revenue mix (service contracts on the global installed imaging equipment base per the disclosed service-economics) provides recurring-revenue stability.
Pharmaceutical Diagnostics is useful mainly because pharmaceutical Diagnostics is useful mainly because the PDx segment (imaging contrast agents per the disclosed product-line) provides diversified high-margin recurring-product mix.
The filing points first to January 2023 GE Spin-Off and Hospital CapEx Cycle when you ask why customers do not switch casually. Siemens / Philips Competition and Post-Spin Capital Allocation show that the advantage is reinforced by adjacent capabilities rather than isolated in one corner of the portfolio. It helps that the FY2024 numbers do not fight the story: January 2023 GE Spin-Off still supported 23.6% ROE alongside a readable cash profile. Per the FY2024 annual report and company disclosures, a rival can still win share, but it has to break an embedded process built around January 2023 GE Spin-Off rather than only undercut a list price.
Capital Allocation
The reason to focus on post-spin capital allocation is that the reason to focus on post-spin capital allocation is that post 2023 spin off capital-allocation includes dividend-initiation plus selective-acquisition strategy per the disclosed strategic-priority communications.
Selective M&A matters in capital allocation because selective M&A matters in capital allocation because GEHC has executed selective bolt-on acquisitions per the disclosed strategic-program communications.
The allocation takeaway from net debt is that the allocation takeaway from net debt is that long-term debt of $8.95B against $2.87B cash equals net debt of $6.08B per the disclosed capital-structure footnote.
Once capex was covered, the business still produced negative free cash flow of $401M, which is the real source of optionality around January 2023 GE Spin-Off and the rest of the file. Per the FY2024 annual report and company disclosures, because capex consumes only 2.0% of revenue, most of the capital-allocation debate happens after the platform is already funded. The cash cushion is real but not excessive: $2.87B against $10.5B of debt keeps the company dependent on operating follow-through. The dividend is still the core capital-return instrument, which keeps attention on coverage and durability.
Key Risks
What hospital capex cycle adds to the risk case is that what hospital capex cycle adds to the risk case is that GEHC's imaging-equipment revenue tracks hospital and imaging center capital equipment spending cycles per the disclosed customer-spending communications.
China Hospital Spending is worth tracking because china Hospital Spending is worth tracking because china hospital equipment spending has been pressured by VBP (volume based procurement) and anti corruption policy dynamics per public industry communications.
The risk significance of siemens / philips competition is that the risk significance of siemens / philips competition is that siemens Healthineers and Philips compete in the same medical imaging and diagnostics market per the disclosed competitive landscape.
The practical risk frame for FY2024 is Hospital CapEx Cycle plus Siemens / Philips Competition, not one clean headline. The linkage between Hospital CapEx Cycle, mix, and cash generation is what makes the risk file worth respecting. Goodwill at 39.7% of assets keeps acquisition discipline and January 2023 GE Spin-Off execution inside the risk conversation. What matters next is whether Hospital CapEx Cycle and Siemens / Philips Competition stay contained at the same time.
Management
Ask about this section
Ask one question here. Keep digging when the issue needs more work.
This analysis is for educational purposes only and does not constitute investment advice.